Effectiveness and safety of rivaroxaban vs. warfarin in patients with non-valvular atrial fibrillation and coronary or peripheral artery disease

拜瑞妥 心房颤动 华法林 医学 心脏病学 内科学 冠状动脉疾病 外围设备 动脉疾病 血管疾病
作者
Craig I Coleman,William L. Baker,Anna‐Katharina Meinecke,Daniel Eriksson,Brandon Martinez,Thomas J. Bunz,Mark J. Alberts
出处
期刊:European Heart Journal - Cardiovascular Pharmacotherapy [Oxford University Press]
卷期号:6 (3): 159-166 被引量:29
标识
DOI:10.1093/ehjcvp/pvz047
摘要

Abstract Aims There are scarce data evaluating the effectiveness and safety of rivaroxaban vs. warfarin in non-valvular atrial fibrillation (NVAF) patients with concomitant coronary artery disease (CAD) and/or peripheral artery disease (PAD) treated in routine practice. Methods and results Using MarketScan data from January 2012 to December 2017, we identified oral anticoagulant (OAC)-naïve NVAF patients receiving rivaroxaban (15–20 mg once daily) or warfarin, with comorbid CAD and/or PAD and ≥12 months of insurance coverage before OAC initiation. Differences in baseline covariates between cohorts were adjusted using inverse probability-of-treatment weights based on propensity scores (standardized differences <0.1 achieved for all covariates after adjustment). Endpoints included a composite of major thrombotic vascular events (MTVEs) (including ischaemic stroke, myocardial infarction, or need for lower limb revascularization/major amputation) and major bleeding. Patients were followed until an event-of-interest, discontinuation/switch of index OAC, insurance disenrolment, or end-of-data availability. Hazard ratios (HRs) and 95% confidence intervals (CIs) were calculated using Cox regression. We identified 3257 rivaroxaban (30.4% received a 15 mg dose) and 5046 warfarin users with NVAF and comorbid CAD and/or PAD. Rivaroxaban was associated with a 32% (95% CI = 8–50%) reduction in the composite of MTVE. No significant difference in major bleeding was observed (HR = 1.13, 95% CI = 0.84–1.52). No statistical interactions were noted in subgroup analyses performed on the MTVE (P-interaction ≥ 0.35 for all) or major bleeding endpoints (P-interaction ≥ 0.09 for all). Conclusion Among patients with NVAF and comorbid CAD and/or PAD, rivaroxaban use was associated with a reduced risk of MTVEs vs. warfarin, without significantly increasing major bleeding risk.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
上官若男的应助被愤怒的迎南采纳,获得10
刚刚
1秒前
1秒前
不安易形发布了新的文献求助10
1秒前
小马甲的应助被hc采纳,获得10
1秒前
2秒前
2秒前
ubless607的应助被神秘墨镜男采纳,获得10
2秒前
2秒前
ubless607的应助被神秘墨镜男采纳,获得10
2秒前
ubless607的应助被神秘墨镜男采纳,获得10
2秒前
打打的应助被Dl采纳,获得10
3秒前
疯子观己身完成签到 ,获得积分10
3秒前
3秒前
李健的应助被科研通管家采纳,获得10
4秒前
bkagyin的应助被JIANGNANYAN采纳,获得10
4秒前
4秒前
Akim的应助被科研通管家采纳,获得10
4秒前
研友_VZG7GZ的应助被科研通管家采纳,获得10
5秒前
852的应助被科研通管家采纳,获得10
5秒前
5秒前
5秒前
5秒前
大模型的应助被科研通管家采纳,获得10
5秒前
Akim的应助被科研通管家采纳,获得10
5秒前
隐形曼青的应助被科研通管家采纳,获得10
5秒前
DW的应助被科研通管家采纳,获得10
6秒前
深情安青的应助被科研通管家采纳,获得10
6秒前
null的应助被科研通管家采纳,获得10
6秒前
傅纶军发布了新的文献求助10
6秒前
6秒前
6秒前
一颗苹果的应助被科研通管家采纳,获得10
6秒前
6秒前
bkagyin的应助被科研通管家采纳,获得10
6秒前
6秒前
7秒前
一颗苹果的应助被科研通管家采纳,获得10
7秒前
molihuakai的应助被科研通管家采纳,获得10
7秒前
一颗苹果的应助被科研通管家采纳,获得10
7秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
八旗制度の研究 600
高分子基功能界面水蒸发材料与应用研究 500
外场增强的水汽发电研究 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8184508
求助须知:如何正确求助?哪些是违规求助? 9573479
关于积分的说明 21831986
捐赠科研通 7781752
什么是DOI,文献DOI怎么找? 3434372
关于科研通互助平台的介绍 2558482
邀请新用户注册赠送积分活动 2480962